Description:

AntibodiestoScl-70areaspecificimmunologicalMarkerforscleroderma(orprogressivesystemicsclerosis,PSS),asystemicautoimmunediseasecharacterizedbycollagendepositionandconnectivetissuedestructionoftheskin,bloodvesselsandcertaininternalorgans.StudieshaveshownvaryingfrequenciesofScl-70antibodiesinPSS.Thisantibodywasfoundinapproximately20%ofPSSpatientsinearlystudiesbut75%inlaterstudies.Scl-70antibodiesaredirectedagainstDNA-topoisomeraseIwhichlocatesinthenucleus.ThewholemoleculeofDNA-topoisomeraseis110kDabutitiseasilydegradedbyproteasesto100kDa,87kDaand70kDa(Scl-70).PSSisclassifiedintotwotypes;diffusesclerodermaandlimitedscleroderma.Scl-70antibodiesarepresentspecificallyindiffusesclerodermaandcentromereantibodiesarepresentinlimitedscleroderma.Rarely,Scl-70antibodiesarefoundinSLEandMCTDpatients.

Principle:

AutoimmuneELISAkitsmeasureautoimmuneantibodiesintheserum.Itisbasedontheprincipleofasolidphaseenzyme-linkedimmunosorbentassay.Theassayutilizesaspecificantigenforimmobilizationonthemicrotiterwellsandanti-humanIgGantibodyconjugatedtohorserADIshperoxidase(HRP)fordetection.Thetestsampleisallowedtoreactsimultaneouslywiththetwocomponents,resultingin autoimmuneantibodiesbeingsandwichedbetweenthesolidphaseandenzyme-linkedantibodies.Afterincubation,thewellsarewashedtoremoveunbound-labeledantibodies.AHRPsubstrate,TMB,isaddedtoresultinthedevelopmentofabluecolor.ThecolordevelopmentisthenstoppedwiththeadditionofStopSolutionchangingthecolortoyellow.Theconcentrationofautoimmuneantibodies isdirectlyproportionaltothecolorintensityofthetestsample.Absorbanceismeasuredspectrophotometricallyat450nm.

Data:

Signosis 是一家专业的生物分析供应商，致力于基于微孔板分析技术的生命科学研究产品的开发、生产和销售。Signosis 成立于2007年，坐落于世界研发中心--美国硅谷的中心地带。公司专注于细胞因子、转录因子、miRNA及疾病标志物等重要调控因子和标志物的研究，基于自有专利技术，开发完成400多种先进而独特的用于发现、筛选和分析的生命科学研究产品。Signosis 产品销售遍布北美、欧洲、亚洲及中东等主要国家和地区，客户涵盖美国国立卫生研究院、哈佛大学、耶鲁大学等著名研究机构以及众多制药公司